News releases

LAWRENCEVILLE, NJ -- (MARKETWIRE) -- 12/19/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that it has received written, scientific advice from the European Medicines Agency (EMA) confirming that the Company's Phase III HEAT Study, a multinational, double-blind, placebo controlled pivotal s...

LAWRENCEVILLE, NJ -- (MARKET WIRE) -- 12/01/11 -- Celsion Corporation (NASDAQ: CLSN) today announced that it has received commitments from investors, including leading life science institutional investors and certain directors of the Company, to purchase an aggregate of $15 million of the Company's securities in a private placement. Closing of...

LAWRENCEVILLE, NJ -- (MARKET WIRE) -- 11/10/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced financial results for the third quarter ended September 30, 2011, and provided a business update including development progress with ThermoDox®, Celsion's proprietary heat-activated liposomal e...

LAWRENCEVILLE, NJ -- (MARKET WIRE) -- 11/03/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it would hold a conference call to discuss third quarter 2011 results at 11:00 a.m. ET on Thursday, November 10, 2011. To participate in the call, interested parties may dial 1-888-427-9380 (To...

COLUMBIA, MD -- (MARKET WIRE) -- 08/25/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today the appointment of Gary Renshaw, D.O., as Executive Medical Director, effective August 29, 2011. Dr. Renshaw will report to Nicholas Borys, M.D., Celsion's Chief Medical Officer. "Gary pos...

COLUMBIA, MD -- (MARKET WIRE) -- 08/17/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today the publication of a clinical and scientific review of ThermoDox®, the Company's proprietary heat-activated liposomal encapsulation of doxorubicin, as a treatment for Hepatocellular Carcinoma (HCC o...

COLUMBIA, MD -- (MARKET WIRE) -- 08/08/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that on August 13, 2011, the Company will convene a clinical symposium in Hong Kong to discuss the reach and market potential of the Company's lead product candidate, ThermoDox®, a proprietary heat-a...

COLUMBIA, MD -- (MARKET WIRE) -- 08/02/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it would hold a conference call to discuss second quarter 2011 results at 11:00 a.m. ET on Tuesday, August 9, 2011. To participate in the call, interested parties may dial 1-866-431-5314 (Toll-Free/...

COLUMBIA, MD -- (MARKET WIRE) -- 07/25/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it expects to relocate its operations and corporate headquarters to Lawrenceville, an area of Lawrence Township in Mercer County, New Jersey. The new headquarters, centrally located between New York...

COLUMBIA, MD -- (MARKET WIRE) -- 07/12/11 -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced the appointment of Gregory Weaver, a Director of Celsion Corporation since 2005, to the role of Senior Vice President and Chief Financial Officer, and the promotion of Jeffery Church, currently Vice Pres...